Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.56 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045489 | 1.00 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL6119573 | 1.00 | GRM8 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3681082 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL3681089 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL30481166 | 0.93 | PTGS1 (0.50) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL22479710 | 0.88 | GRM8 (0.52) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL11957999 | 0.88 | GRM8 (0.52) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL2483655 | 0.88 | BLM (0.55) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL16203683 | 0.88 | PTGS1 (0.56) | GRM8GRM6GRIN2DGRIN3BGSR | |
| SCHEMBL2483653 | 0.88 | BLM (0.55) | GRM8GRM6GRIN2DGRIN3BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1988007851-A1 | LIPOSOME ENTRAPPED N-METHYL-D-ASPARTATE RECEPTOR BLOCKERS | INNOVATIVE THERAPEUTICS CORPORATION (US) | 1988-10-20 | — | — | WO | claimed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230393140-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI INTERNATIONAL (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4229211-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI International (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022082006-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI INTERNATIONAL (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2021046549-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-5945509-A | A POLYPEPTIDE THAT CODES FOR A MEMBRANE PROTEIN INVOLVED IN NEUROTRANSMISSION; THERAPY AND DIAGNOSIS OF NERVOUS SYSTEMDISORDERS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-08-31 | — | — | US | disclosed |
| US-5739291-A | MONOCLONAL ANTIBODY BINDS TO GENETIC ENGINEERED PROTEIN | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1998-04-14 | — | — | US | disclosed |
| US-5202257-A | Pure DNA which is capable of hybridizing with receptor polynucleotides under mild conditions | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1993-04-13 | — | — | US | disclosed |
| WO-1988007851-A1 | LIPOSOME ENTRAPPED N-METHYL-D-ASPARTATE RECEPTOR BLOCKERS | INNOVATIVE THERAPEUTICS CORPORATION (US) | 1988-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | GRM8 3854/4885GRM6 4063/4885GRIN2D 4290/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | GRM8 3854/4885GRM6 4063/4885GRIN2D 4290/4885 |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | GRM8 3854/4885GRM6 4063/4885GRIN2D 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.